HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Drug Profile

HSP105 peptide-pulsed dendritic cell vaccine - Medinet

Alternative Names: Cytotoxic T-lymphocyte stimulants-based cancer vaccine - Medinet; Dendritic cell-stimulated vaccine - Medinet; Heat shock protein 105 peptide-pulsed dendritic cell vaccine - Medinet; HSP105-derived cancer antigen peptide vaccine - Medinet

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medinet
  • Developer Medinet; University of Tokyo
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer
  • No development reported Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Renal-cell-carcinoma(Combination therapy, Late-stage disease) in Japan (Parenteral)
  • 15 Nov 2011 Phase-II clinical trials in Cancer (late-stage disease) in Japan (Parenteral) (UMIN000006730)
  • 31 Mar 2009 Medinet acquires a licence to patents for HSP105-derived peptides from Kumamoto Technology and Industrial Foundation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top